Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent

Enfortumab vedotin (EV), a nectin-4-directed antibody conjugated to monomethyl auristatin E (MMAE), has been approved for patients with advanced urothelial carcinoma (aUC) previously treated with platinum-based chemotherapy and immune inhibitors. Taxane agents and MMAE share antitumor mechanisms thr...

Full description

Bibliographic Details
Main Authors: Makito Miyake, Nobutaka Nishimura, Tatsuki Miyamoto, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Tomomi Fujii, Kiyohide Fujimoto
Format: Article
Language:English
Published: Hindawi Limited 2023-01-01
Series:Case Reports in Urology
Online Access:http://dx.doi.org/10.1155/2023/1024239

Internet

http://dx.doi.org/10.1155/2023/1024239

Similar Items